Incidence Rates of Soft Tissue Sarcoma Lower in Servicemen
MONDAY, Dec. 9, 2024 -- The incidence rates of soft tissue sarcoma (STS) are lower among servicemen than men in the general U.S. population, according to a study published online Dec. 9 in Cancer.
Julie A. Bytnar, Dr.P.H., from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and colleagues compared the incidence of STS from 1990 to 2013 between active‐duty servicemen in the Department of Defense Automated Central Tumor Registry (ACTUR) and men in the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program, aged 18 to 59 years.
The researchers found that STS incidence rates were lower in ACTUR than SEER overall and for 18- to 39-year-old men (incidence rate ratio [IRRs], 0.86 and 0.78, respectively). Incidence rates were also lower by race (IRRs, 0.85 and 0.77 for Whites and Blacks, respectively), for sites other than skin/connective/soft tissue (IRR, 0.49), for other specified histologies and for unspecified histology (IRRs, 0.84 and 0.57, respectively). Even when stratified by race and age, rates were lower in ACTUR for regional and distant metastases (IRRs, 0.37 and 0.58, respectively). For 40- to 59-year-old men and localized tumors, rates were higher in ACTUR (IRRs, 1.25 and 1.16, respectively).
"We found lower incidence rates and earlier‐stage STS disease among active‐duty military servicemen than the general U.S. population. This may result from earlier detection and treatment, better baseline health, and access to health care," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.